We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SABS SAB Biotherapeutics Inc

0.00 (0.0%)
Pre Market
Last Updated: 07:00:14
Delayed by 15 minutes


Draw Mode:

Volume 0
Bid Price 0.41
Ask Price 0.90
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
SAB Biotherapeutics Inc SABS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.888 07:00:14
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 0.3657 - 1.45
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.888 USD

SAB Biotherapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
46.56M 52.32M - 23.9M -18.74M -0.36 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

SAB Biotherapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No SABS Message Board. Create One! See More Posts on SABS Message Board See More Message Board Posts

Historical SABS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.960.970.850.9107884131,619-0.072-7.5%
1 Month0.960.97210.630.90684372,425-0.072-7.5%
3 Months0.601.050.410.836264165,3110.28848.0%
6 Months0.92021.050.410.823840758,473-0.0322-3.5%
1 Year1.001.450.36570.9106832383,752-0.112-11.2%
3 Years7.8012.090.36572.62272,378-6.91-88.62%
5 Years7.8012.090.36572.62272,378-6.91-88.62%

SAB Biotherapeutics Description

SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing fully human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The company's lead asset, SAB-142, targets Type-1 diabetes (T1D) with a disease-modifying therapeutic approach that aims at changing the treatment paradigm by delaying onset and potentially preventing disease progression.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |